hotspot -WSS

hotspot

author：leisure time 2025-10-01 17:20:16 - browse：26363

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

hotspot

entertainment

WSS

Custom gene therapy hints at new path for rare disease treatments

As digital health tech proliferates, a new institute aims to cut through hype

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Google and Epic fight stronger regulation of AI in health care

knowledge

hotspot

hotspot

Heart attack and stroke risk calculators need revising

A daunting task: navigating dual Medicare, Medicaid eligibility

Affirmative action in medical school literally saved lives

A public scorecard can help hold safety

Anesthesiologist group: stop taking Ozempic before surgery

CRISPR pioneers react to Casgevy, first gene

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

David Sabatini, ex

Trump demands the U.S. pay no more for drugs than other countries … again

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

hotspot

Why medical students are struggling with mental health

Congress must reauthorize a committee to support older Americans

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Gain of function research would be limited under House proposal

How dance can help nurses traumatized by Covid

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

hotspot

entertainment

knowledge

hotspot